IP Library Granted Patent US 9,144,576
Granted Patent B2
US 9,144,576 · App. 14/094,061 · Granted Sep 29, 2015

Topical antiviral formulations

Inventors: Darby C. Brown (Parker, CO); Kristen A. Brown (Parker, CO)
Assignee: 3B Pharmaceuticals, Inc.
A61K31/7004A61K9/0014A61K31/522
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,144,576
App. No.
14/094,061
Granted
Sep 29, 2015
Kind
B2
Abstract

The disclosure provides antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.

Claims (25)

1. A topical pharmaceutical composition comprising a therapeutically effective amount of an antiviral compound selected from one or more of the group consisting of acyclovir, or a pharmaceutically acceptable salt or hydrate thereof; and

a therapeutically effective amount of 2-deoxy-D-glucose.

2. The composition of claim 1 , wherein the antiviral compound is acyclovir.

3. The composition of claim 1 in a form selected from a lip-balm, stick, cream or ointment.

4. The composition of claim 3 in a lip-balm form.

5. The composition of claim 4 , further comprising one or more polyethylene glycols.

6. The composition of claim 5 , further comprising one or more sweeteners or flavorings.

7. The composition of claim 6 , wherein the sweetener is stevioside.

8. The composition of claim 6 , wherein the flavoring is spearmint oil.

9. The composition of claim 2 , wherein the composition comprises from about 3 wt % to about 7 wt % of acyclovir and from about 0.1 wt % to about 5 wt % of 2-deoxy-D-glucose.

10. The composition of claim 9 , wherein the composition comprises about 5 wt % of acyclovir and about 0.2 wt % of 2-deoxy-D-glucose.

11. A method of treating a herpes viral infection of a patient in need thereof comprising topically administering a pharmaceutical composition comprising a therapeutically effective amount of an antiviral compound selected from the group consisting of acyclovir, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of 2-deoxy-D-glucose.

12. The method of claim 11 , wherein the antiviral compound is acyclovir.

13. The method of claim 11 , wherein the composition is in a form selected from a lip-balm, stick, cream or ointment.

14. The method of claim 13 , wherein the composition is in a lip-balm form.

15. The method of claim 12 , wherein the composition comprises from about 3 wt % to about 7 wt % of acyclovir and from about 0.1 wt % to about 5 wt % of 2-deoxy-D-glucose.

16. The method of claim 15 , wherein the topical comprises about 5 wt % of acyclovir and about 0.2 wt % of 2-deoxy-D-glucose.

17. The method of claim 11 , wherein the treatment is for latent infection of herpes simplex type 1 infection.

18. The method of claim 11 , wherein the treatment is for latent infection of herpes simplex type 2 infection.

19. The method of claim 11 , wherein the infection is an orofacial herpes infection.

20. A method of reducing the duration of a herpes viral infection outbreak in a mammal in need thereof comprising topically administering a pharmaceutical composition comprising a therapeutically effective amount of an antiviral compound selected from the group consisting of acyclovir, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of 2-deoxy-D-glucose.

21. The method of claim 20 , wherein the antiviral compound is acyclovir.

22. The method of claim 20 , wherein the treatment is for latent infection of herpes simplex type 1 infection.

23. The method of claim 20 , wherein the treatment is for latent infection of herpes simplex type 2 infection.

24. The method of claim 20 , wherein the infection is an orofacial herpes infection.

Continuity (4)
Continuation 13523471 · Jun 14, 2012
Continuation 12572584 · Oct 2, 2009
Provisional Application 61102729 · Oct 3, 2008
Related Publication 20140221297A1 · Aug 7, 2014